We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Teleflex Gets FDA’s 510(k) Clearance for Expanded Indication for Specialty Catheter

Teleflex Gets FDA’s 510(k) Clearance for Expanded Indication for Specialty Catheter

March 2, 2022

Teleflex has received the FDA’s 510(k) clearance for an expanded indication for several specialty catheters and coronary guidewires for use in crossing chronic total occlusions in coronary arteries.

The agency granted the expanded indication to the Teleflex GuideLiner V3, TrapLiner and Turnpike catheters, and to the Spectre, Raider, Bandit, Warrior and R350 guidewires, the company said.

The devices were evaluated in an investigational device exemption study that enrolled 150 patients in 13 sites across the U.S. Technical success, defined as successful guidewire recanalization, was achieved in 93.3 percent of cases, and procedural success — freedom from major adverse cardiovascular events — was achieved in more than 75 percent of cases, the company said.

View today's stories

Devices Submissions and Approvals

    Upcoming Events

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • EMA Expands Review of GLP-1 Agonists and Suicide, While Weight Loss Drug Market Looks to Expand

    • FDA Urges Avoiding Plastic Syringes Made in China Due to Device Failures

    • FDA Laboratory-Developed Tests Proposal Comments Pour In by Thousands

    • Healthcare Titans Expand Their Portfolios in Acquisition Deals

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing